Clobazam is a long half-life benzodiazepine used as anxiolytic and in combination with other drugs is prescribed to treat seizures caused by epilepsy.
Its mechanism of action is to increase the activity of GABA by facilitating its binding to the GABAergic receptor.
Hypersensitivity to clobazam and to benzodiazepines.
Myasthenia gravis, sleep apnea syndrome, severe respiratory insufficiency, severe hepatic impairment, angle-closure glaucoma.
Do not ingest during lactation.
Do not administer to children younger than 3 years, except in cases where treatment is essential; do not administer in the elderly. Psychiatric and paradoxical reactions are more common in children and elderly patients.
Clobazam intake can lead to liver failure, renal failure and chronic or acute respiratory failure.
Poor clobazam metabolizers individuals (see technical report) may need dosage adjustment.
In patients with preexisting muscle weakness or spinal or cerebellar ataxia, special monitoring and dose reduction of the drug must be performed.
After continued use of the drug there is risk of tolerance and of physical-psychic dependence. Abrupt discontinuation after continued use causes abstinence syndrome. Do not use in anxiety associated with depression nor as primary treatment of psychotic illness.
Somnolence, affective disorders, reduced alertness, confusion, fatigue, headache, dizziness, vertigo, muscle hypotonia, muscle weakness, ataxia, diplopia, amnesia, depression, psychiatric and paradoxical reactions, dry mouth, constipation, decreased appetite, nausea, weight gain and dependence.
- - Noiafen ®
- - Onfi ®
Gene or region studied